REFERENCES
1. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-84.
2. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6.
3. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
4. Barriere G, Fici P, Gallerani G, Fabbri F, Rigaud M. Epithelial mesenchymal transition: a double-edged sword. Clin Transl Med 2015;4:14.
6. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.
7. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28.
8. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54.
9. Vesuna F, van Diest P, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 2008;367:235-41.
10. Mizushima N, Ohsumi Y, Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct 2002;27:421-9.
11. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290:1717-21.
13. Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, et al. Mammalian autophagy: how does it work? Ann Rev Biochem 2016;85:685-713.
14. Eskelinen EL, Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta 2009;1793:664-73.
15. Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ 2005;12:1542-52.
16. Saha S, Panigrahi DP, Patil S, Bhutia SK. Autophagy in health and disease: a comprehensive review. Biomed Pharmacother 2018;104:485-95.
17. Araya J, Kojima J, Takasaka N, Ito S, Fujii S, et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2013;304:L56-69.
18. Patel AS, Lin L, Geyer A, Haspel JA, An CH, et al. Autophagy in idiopathic pulmonary fibrosis. PLoS One 2012;7:e41394.
19. Hill C, Li J, Liu D, Conforti F, Brereton CJ, et al. Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death Dis 2019;10:591.
20. Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 2012;8:108-17.
21. Wang Y, Xiong H, Liu D, Hill C, Ertay A, et al. Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells. Autophagy 2019;15:886-99.
23. Singh SS, Vats S, Chia AYQ, Tan TZ, Deng S, et al. Dual role of autophagy in hallmarks of cancer. Oncogene 2018;37:1142-58.
24. Bhutia SK, Mukhopadhyay S, Sinha N, Das DN, Panda PK, et al. Autophagy: cancer’s friend or foe? Adv Cancer Res 2013;118:61-95.
25. Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014;5:3056.
26. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011;25:795-800.
27. Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, et al. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res 2012;18:370-9.
28. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012;12:401-10.
29. Sun K, Deng W, Zhang S, Cai N, Jiao S, et al. Paradoxical roles of autophagy in different stages of tumorigenesis: protector for normal or cancer cells. Cell Biosci 2013;3:35.
30. Classen F, Kranz P, Riffkin H, Pompsch M, Wolf A, et al. Autophagy induced by ionizing radiation promotes cell death over survival in human colorectal cancer cells. Exp Cell Res 2019;374:29-37.
31. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011;25:460-70.
32. Yang S, Wang X, Contino G, Liesa M, Sahin E, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011;25:717-29.
33. Fitzwalter BE, Towers CG, Sullivan KD, Andrysik Z, Hoh M, et al. Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover. Dev Cell 2018;44:555-65.e3.
34. Rupniewska E, Roy R, Mauri FA, Liu X, Kaliszczak M, et al. Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. Oncotarget 2018;9:27346-62.
35. Chen X, Clark J, Guan J, Kumar AR, Zheng Y. Susceptibility of AML to chloroquine therapy is independent of autophagy. Blood 2015;126:1262.
36. Gugnoni M, Sancisi V, Manzotti G, Gandolfi G, Ciarrocchi A. Autophagy and epithelial-mesenchymal transition: an intricate interplay in cancer. Cell Death Dis 2016;7:e2520.
37. Chen HT, Liu H, Mao MJ, Tan Y, Mo XQ, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy. Mol Cancer 2019;18:101.
38. Qin W, Li C, Zheng W, Guo Q, Zhang Y, et al. Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells. Oncotarget 2015;6:39839-54.
39. Alizadeh J, Glogowska A, Thliveris J, Kalantari F, Shojaei S, et al. Autophagy modulates transforming growth factor beta 1 induced epithelial to mesenchymal transition in non-small cell lung cancer cells. Biochim Biophys Acta Mol Cell Res 2018;1865:749-68.
40. Qiang L, He YY. Autophagy deficiency stabilizes TWIST1 to promote epithelial-mesenchymal transition. Autophagy 2014;10:1864-5.
41. Shen H, Yin L, Deng G, Guo C, Han Y, et al. Knockdown of Beclin-1 impairs epithelial-mesenchymal transition of colon cancer cells. J Cell Biochem 2018;119:7022-31.
42. Liang C, Xu J, Meng Q, Zhang B, Liu J, et al. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Autophagy 2019:1-15.
43. Peng YF, Shi YH, Ding ZB, Ke AW, Gu CY, et al. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy 2013;9:2056-68.
44. Lv Q, Hua F, Hu ZW. DEDD, a novel tumor repressor, reverses epithelial-mesenchymal transition by activating selective autophagy. Autophagy 2012;8:1675-6.
45. Zi D, Zhou ZW, Yang YJ, Huang L, Zhou ZL, et al. Danusertib induces apoptosis, cell cycle arrest, and autophagy but inhibits epithelial to mesenchymal transition involving PI3K/Akt/mTOR signaling pathway in human ovarian cancer cells. Int J Mol Sci 2015;16:27228-51.
46. Wei R, Xiao Y, Song Y, Yuan H, Luo J, et al. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res 2019;38:112.
47. Avivar-Valderas A, Bobrovnikova-Marjon E, Alan Diehl J, Bardeesy N, Debnath J, et al. Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK. Oncogene 2013;32:4932-40.
48. Su Z, Li G, Liu C, Ren S, Deng T, et al. Autophagy inhibition impairs the epithelial-mesenchymal transition and enhances cisplatin sensitivity in nasopharyngeal carcinoma. Oncol Lett 2017;13:4147-54.
49. Wei R, Xiao Y, Song Y, Yuan H, Luo J, et al. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res 2019;38:112.
50. Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis 2018;35:309-18.
51. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, et al. Drug resistance in cancer: an overview. Cancers (Basel) 2014;6:1769-92.
52. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, et al. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992;52:5190-7.
53. Fischer KR, Durrans A, Lee S, Sheng J, Li F, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527:472-6.
54. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009;69:5820-8.
55. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527:525-30.
56. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009;28:335-44.
57. Huang J, Li H, Ren G. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol 2015;47:840-8.
58. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011;2:e179.
59. Li J, Liu H, Yu J, Yu H. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Mol Med Rep 2015;12:192-8.
60. Wu Y, Ginther C, Kim J, Mosher N, Chung S, et al. Expression of Wnt3 activates Wnt/-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res 2012;10:1597-606.
61. Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, et al. SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer. Clin Cancer Res 2015;21:4686-97.
62. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009;69:2400-7.
63. Xu X, Zhang L, He X, Zhang P, Sun C, et al. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochem Biophys Res Commun 2018;502:160-5.
64. Oshimori N, Oristian D, Fuchs E. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 2015;160:963-76.
65. Katsuno Y, Meyer DS, Zhang Z, Shokat KM, Akhurst RJ, et al. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci Signal 2019;12:eaau8544.
66. Zhang Y, Zhang Y, Geng L, Yi H, Huo W, et al. Transforming growth factor β mediates drug resistance by regulating the expression of pyruvate dehydrogenase kinase 4 in colorectal cancer. J Biol Chem 2016;291:17405-16.
67. Li RN, Liu B, Li XM, Hou LS, Mu XL, et al. DACT1 overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy. Sci Rep 2017;7:9285.
68. Ma X, Wang B, Wang X, Luo Y, Fan W. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells. PloS One 2018;13:e0192436.
69. Park SH, Jo MJ, Kim BR, Jeong YA, Na YJ, et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics 2019;9:2235-51.
70. Deng JJ, Zhang W, Xu XM, Zhang F, Tao WP, et al. Twist mediates an aggressive phenotype in human colorectal cancer cells. Int J Oncol 2016;48:1117-24.
71. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004;23:474-82.
72. Chen Y, Li L, Zeng J, Wu K, Zhou J, et al. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein. Chemotherapy 2012;58:264-72.
73. Wang L, Tan RZ, Zhang ZX, Yin R, Zhang YL, et al. Association between Twist and multidrug resistance gene-associated proteins in Taxol(®)-resistant MCF-7 cells and a 293 cell model of Twist overexpression. Oncol Lett 2018;15:1058-66.
74. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012;12:91.
75. Hojo N, Huisken AL, Wang H, Chirshev E, Kim NS, et al. Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer. Sci Rep 2018;8:8704.
76. Nakamura R, Ishii H, Endo K, Hotta A, Fujii E, et al. Reciprocal expression of Slug and Snail in human oral cancer cells. PLoS One 2018;13:e0199442.
77. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30.
78. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011;2:e179.
79. Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 2013;5:1196-212.
80. Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer 2012;11:87.
81. Li N, Babaei-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, et al. An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis 2019;8:13.
82. Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem 2014;289:17163-73.
83. Bao L, Jaramillo MC, Zhang Z, Zheng Y, Yao M, et al. Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. Mol Med Rep 2015;11:91-8.
84. You Y, Bi FF, Jiang Y, Xu YT, An YY, et al. BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy. Cancer Med 2019;8:656-68.
85. Lee JG, Shin JH, Shim HS, Lee CY, Kim DJ, et al. Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions. Respir Res 2015;16:138.
86. Liu D, Yang Y, Liu Q, Wang J. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol 2011;28:105-11.
87. Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther 2013;14:100-7.
88. Shuhua W, Chenbo S, Yangyang L, Xiangqian G, Shuang H, et al. Autophagy-related genes Raptor, Rictor, and Beclin1 expression and relationship with multidrug resistance in colorectal carcinoma. Hum Pathol 2015;46:1752-9.
89. Sui X, Kong N, Wang X, Fang Y, Hu X, et al. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sci Rep 2014;4:4694.
90. Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 2010;46:1900-9.
91. Liang X, Tang J, Liang Y, Jin R, Cai X. Suppression of autophagy by chloroquine sensitizes 5-fluorouracil-mediated cell death in gallbladder carcinoma cells. Cell Biosci 2014;4:10.
92. Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 2008;7:2977.
93. Chen Z, Jiang Q, Zhu P, Chen Y, Xie X, et al. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer. Prostate 2019;79:44-53.
94. Sun WL, Chen J, Wang YP, Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011;7:1035-44.
95. Xiao X, Wang W, Li Y, Yang D, Li X, et al. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res 2018;37:201.
96. An Y, Zhang Z, Shang Y, Jiang X, Dong J, et al. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis 2015;6:e1766.
97. O’Donovan TR, O’Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 2011;7:509-24.
98. Zhang LH, Yang AJ, Wang M, Liu W, Wang CY, et al. Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. Apoptosis 2016;21:473-88.
99. Zhang N, Qi Y, Wadham C, Wang L, Warren A, et al. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy 2010;6:1157-67.
100. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010;3:ra81.
101. Ahn JH, Lee M. Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. Cancer Lett 2011;310:188-97.
102. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007;110:313.
103. Ge J, Chen Z, Huang J, Chen J, Yuan W, et al. Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer. PLoS One 2014;9:e110293.
104. Claerhout S, Verschooten L, Van Kelst S, De Vos R, Proby C, et al. Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma. Int J Cancer 2010;127:2790-803.
